KR20060052807A - 항염증 활성을 가지는 특이적 글루코코르티코스테로이드화합물 - Google Patents
항염증 활성을 가지는 특이적 글루코코르티코스테로이드화합물 Download PDFInfo
- Publication number
- KR20060052807A KR20060052807A KR1020067000738A KR20067000738A KR20060052807A KR 20060052807 A KR20060052807 A KR 20060052807A KR 1020067000738 A KR1020067000738 A KR 1020067000738A KR 20067000738 A KR20067000738 A KR 20067000738A KR 20060052807 A KR20060052807 A KR 20060052807A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- oxo
- hydroxy
- oxy
- difluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (22)
- 하기 화학식(I)의 화합물 또는 이들의 생리학적으로 허용되는 염 또는 용매화물:상기 식에서,X는 O 또는 S를 나타내고;R1은 C1-6 알킬, C3-8 시클로알킬, C3-8 시클로알킬메틸 또는 C3-8 시클로알케닐 (이들 중 임의의 것은 선택적으로 하나 이상의 메틸기 또는 할로겐 원자로 치환될 수 있다)을 나타내거나 , R1은 아릴, 치환된 아릴, 헤테로아릴 또는 치환된 헤테로아릴을 나타내며;R2는 수소, α 또는 β 배열로 위치하고 있는 메틸, 또는 메틸렌을 나타내며;R3 및 R4는 동일하거나 상이하며, 각각은 독립적으로 수소, 할로겐 또는 메틸기를 나타내며;
- 제 1 항에 있어서, X는 O를 나타냄을 특징으로 하는 화합물.
- 제 1 항 또는 제 2 항에 있어서, R1이 하나 이상의 메틸 또는 염소로 치환되거나 비치환된 C3-6 시클로알킬기를 나타냄을 특징으로 하는 화합물.
- 제 1 항 내지 제 3 항 중 어느 한 항에 있어서, R1이 2,2,3,3-테트라메틸시클로프로필을 나타냄을 특징으로 하는 화합물.
- 제 1 항 내지 제 4 항 중 어느 한 항에 있어서, R2이 α-배열로 위치하는 메틸을 나타내는 화합물.
- 제 1 항 내지 제 5 항 중 어느 한 항에 있어서, R3 및 R4 둘 모두가 플루오르임을 특징으로 하는 화합물.
- 제 1 항 내지 제 7 항 중 어느 한 항에 있어서,6α,9α-디플루오로-11β-하이드록시-l6α-메틸-3-옥소-l7α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;l7α-(4-[(디에틸아미노)설포닐]벤조일)옥시-6α,9α-디플루오로-11β-하이드록시-l6α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;l7α-(5-클로로-4-메톡시-티오펜-3-카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-l6α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-l6α-메틸-3-옥소-l7α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-1,4-디엔-17β-카르복실산 시아노메 틸 에스테르;l7α-(시클로헥실카르보닐)옥시-6α,9α-디플루오로-1lβ-하이드록시-l6α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-l7α-(2,6-디플루오로벤조일)옥시-11β-하이드록시-l6α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-l7α-(4-메톡시벤조일)옥시-l6α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;l7α-(4-시아노벤조일)옥시-6α,9α-디플루오로-11β-하이드록시-l6α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;l7α-(시클로펜틸메틸카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-l6α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-l7α-(3,3-디메틸부타노일)옥시-11β-하이드록시-l6α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-l7α-(2-이소프로필-1,3-티아졸-4-카르보닐)옥시-l6α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-l6α-메틸-3-옥소-l7α-(퀴놀린-2-카르보닐)옥시-안드로스타-l,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-l6α-메틸-3-옥소-17α-(5-트리플루오로메틸-푸란-2-카르보닐)옥시-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에 스테르;6α,9α-디플루오로-11β-하이드록시-l6α-메틸-l7α-(5-메틸설포닐-티오펜-2-카르보닐)옥시-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-l6α-메틸-l7α-(5-메틸티오-티오펜-2-카르보닐)옥시-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-l7α-(5-에틸-이속사졸-3-카르보닐)옥시-11β-하이드록시-l6α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;9α-플루오로-11β-하이드록시-16β-메틸-3-옥소-l7α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-l6α-메틸-3-옥소-l7α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-4-엔-17β-카르복실산 시아노메틸 에스테르;l7α-(5-클로로-4-메톡시-티오펜-3-카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-l6α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;l7α-(2,2-디클로로-3,3-디메틸클로프로필카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-l6α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;l7α-(2,2-디클로로-3,3-디메틸클로프로필카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-l6α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;l7α-(시클로헥실카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-l6α-메틸-l7α-(5-메틸설포닐-티오펜-2-카르보닐)옥시-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S- 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-l6α-메틸-3-옥소-l7α-(5-트리플루오로메틸-푸란-2-카르보닐)옥시-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르; 또는6α,9α-디플루오로-l7α-(3-(디플루오로메틸티오)벤조일)옥시-11β-하이드록시-l6α-메틸-3-옥소-안드로스타-l,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르인임을 특징으로 하는 화합물.
- 제 8 항에 있어서, 화합물이6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;9α-플루오로-11β-하이드록시-16β-메틸-3-옥소-17α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;17α-(시클로헥실카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;17α-(시클로펜틸메틸카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-17α-(3,3-디메틸부타노일)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-17α-(3-(디플루오로메틸티오)벤조일)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;17α-(시클로헥실카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르;6α,9α-디플루오로-17α-(5-에틸-이속사졸-3-카르보닐)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-16α-메틸-17α-(5-메틸티오-티오펜-2- 카르보닐)옥시-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-17α-(2-이소프로필-1,3-티아졸-4-카르보닐)옥시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;17α-(2,2-디클로로-3,3-디메틸클로프로필카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르; 또는17α-(2,2-디클로로-3,3-디메틸클로프로필카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르.
- 제 9 항에 있어서,17α-(2,2-디클로로-3,3-디메틸클로프로필카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산 시아노메틸 에스테르;6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-1,4-디엔-17β-카르보티오산 S-시아노메틸 에스테르; 또는6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-1,4-디엔-17β-카르복실산 시아노메 틸 에스테르임을 특징으로 하는 화합물.
- 제 10 항에 있어서,6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(2,2,3,3-테트라메틸시클로프로필카르보닐)옥시-안드로스타-l,4-디엔-17β-카르복실산 시아노메틸 에스테르임을 특징으로 하는 화합물.
- 동물 또는 인간 의약에 사용하기 위한 제 1 항 내지 제 11 항 중 어느 한 항에 따른 화학식(I)의 화합물 또는 이들의 생리학적으로 허용하는 용매화물.
- 제 1 항 내지 제 11 항 중 어느 한 항에 따른 화학식(I)의 화합물 또는 이들의 생리학적으로 허용하는 용매화물의 염증 및/또는 알레르기 질환의 치료를 위한 약제 제조용 용도
- 제 1 항 내지 제 11 항 중 어느 한 항에 따른 화학식(I)의 화합물 또는 이들의 생리학적으로 허용하는 용매화물을 요망되는 경우 하나 이상의 생리학적으로 허용되는 희석제 또는 담체와 혼합하여 포함하는 약제 조성물.
- 제 1 항 내지 제 11 항 중 어느 한 항에 따른 화학식(I)의 화합물 또는 이들의 생리학적으로 허용되는 용매화물 및 추진제로서 플루오로탄소 또는 수소-함유 클로로플루오로 탄소를, 선택적으로 계면활성제 및/또는 공용매와 조합하여, 포함하는 약학적 에어로졸 제형.
- 제 15 항에 있어서, 다른 치료용 활성제를 추가함을 특징으로 하는 약제 조성물.
- 제 16 항에 있어서, 상기 다른 치료용 활성제가 β2-아드레노수용제 작용제임을 특징으로 하는 약제 조성물.
- 제 1 항 내지 제 11 항 중 어느 한 항에 따른 화학식(I)의 화합물 또는 이들의 생리학적으로 허용되는 용매화물의 유효량을 사람 또는 동물에게 투여하는 것을 포함하여, 항염증 및/또는 알레르기 질환을 가진 인간 또는 동물의 치료 방법.
- 17α-(4-[(디에틸아미노)설포닐]벤조일)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산;6α,9α-디플루오로-17α-(2,6-디플루오로벤조일)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;6α,9α-디플루오로-11β-하이드록시-17α-(4-메톡시벤조일)옥시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;17α-(4-시아노벤조일)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;6α,9α-디플루오로-17α-(3,3-디메틸부타노일)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;6α,9α-디플루오로-11β-하이드록시-17α-(2-이소프로필-1,3-티아졸-4-카르보닐)옥시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(퀴놀린-2-카르보닐)옥시-안드로스타-1,4-디엔-17β-카르복실산;6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-17α-(5-트리플루오로메틸-푸란-2-카르보닐)옥시-안드로스타-1,4-디엔-17β-카르복실산;6α,9α-디플루오로-11β-하이드록시-16α-메틸-17α-(5-메틸설포닐-티오펜-2-카르보닐)옥시-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;6α,9α-디플루오로-11β-하이드록시-16α-메틸-17α-(5-메틸티오-티오펜-2-카르보닐)옥시-3-옥소-안드로스타-l,4-디엔-17β-카르복실산;6α,9α-디플루오로-17α-(5-에틸-이속사졸-3-카르보닐)옥시-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;17α-(5-클로로-4-메톡시-티오펜-3-카르보닐)옥시-6α,9α-디플루오로-11 β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실산;17α-(2,2-디클로로-3,3-디메틸클로프로필카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-1,4-디엔-17β-카르복실 산;17α-(2,2-디클로로-3,3-디메틸클로프로필카르보닐)옥시-6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-안드로스타-l,4-디엔-17β-카르보티오산;6α,9α-디플루오로-11β-하이드록시-l6α-메틸-17α-(5-메틸설포닐-티오펜-2-카르보닐)옥시-3-옥소-안드로스타-1,4-디엔-17β-카르보티오산;6α,9α-디플루오로-11β-하이드록시-16α-메틸-3-옥소-l7α-(5-트리플루오로메틸-푸란-2-카르보닐)옥시-안드로스타-1,4-디엔-17β-카르보티오산, 또는6α,9α-디플루오로-17α-(3-(디플루오로메틸티오)벤조일)옥시-11β-하이드록시-l6α-메틸-3-옥소-안드로스타-l,4-디엔-17β-카르보티오산임을 특징으로 하는 화합물.
- 제 21 항에 있어서, X가 O를 나타냄을 특징으로 하는 공정.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0316290.6 | 2003-07-11 | ||
GBGB0316290.6A GB0316290D0 (en) | 2003-07-11 | 2003-07-11 | Novel compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060052807A true KR20060052807A (ko) | 2006-05-19 |
KR101075324B1 KR101075324B1 (ko) | 2011-10-19 |
Family
ID=27742019
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067000690A KR101029207B1 (ko) | 2003-07-11 | 2004-07-09 | 소염 활성을 지니는 특정 글루코코르티코스테로이드 화합물 |
KR1020067000738A KR101075324B1 (ko) | 2003-07-11 | 2004-07-09 | 항염증 활성을 가지는 특이적 글루코코르티코스테로이드화합물 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067000690A KR101029207B1 (ko) | 2003-07-11 | 2004-07-09 | 소염 활성을 지니는 특정 글루코코르티코스테로이드 화합물 |
Country Status (31)
Country | Link |
---|---|
US (6) | US7291609B2 (ko) |
EP (3) | EP1644397B1 (ko) |
JP (3) | JP4709752B2 (ko) |
KR (2) | KR101029207B1 (ko) |
CN (3) | CN1845933B (ko) |
AR (2) | AR045900A1 (ko) |
AT (1) | ATE467638T1 (ko) |
AU (2) | AU2004255855B2 (ko) |
BR (2) | BRPI0412526A (ko) |
CA (2) | CA2531905C (ko) |
CY (2) | CY1110149T1 (ko) |
DE (1) | DE602004027137D1 (ko) |
DK (2) | DK1644397T3 (ko) |
ES (3) | ES2433665T3 (ko) |
GB (1) | GB0316290D0 (ko) |
HK (2) | HK1089186A1 (ko) |
HR (2) | HRP20100359T1 (ko) |
IL (3) | IL172777A (ko) |
IS (3) | IS2909B (ko) |
MA (2) | MA27899A1 (ko) |
MX (2) | MXPA06000443A (ko) |
MY (2) | MY137944A (ko) |
NO (2) | NO333263B1 (ko) |
NZ (2) | NZ544577A (ko) |
PL (2) | PL1644397T3 (ko) |
PT (2) | PT1644397E (ko) |
RU (3) | RU2359973C2 (ko) |
SI (2) | SI1644398T1 (ko) |
TW (2) | TWI367888B (ko) |
WO (2) | WO2005005452A1 (ko) |
ZA (2) | ZA200600226B (ko) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0125259D0 (en) * | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
DE102004025966A1 (de) * | 2004-05-21 | 2005-12-15 | Schering Ag | Estradiol-Prodrugs |
DE102004025985A1 (de) * | 2004-05-21 | 2005-12-15 | Schering Ag | Estriol- und Estetrol-Prodrugs |
US20090124588A1 (en) * | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
ATE517908T1 (de) * | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
EP1879620A2 (en) * | 2005-03-30 | 2008-01-23 | Schering Corporation | Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist |
EP1921919B1 (en) | 2005-07-14 | 2012-04-04 | Lithera, Inc. | Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
ES2388351T3 (es) | 2006-04-20 | 2012-10-11 | Glaxo Group Limited | Compuestos novedosos |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
WO2008048770A1 (en) * | 2006-10-17 | 2008-04-24 | Lipothera, Inc. | Methods, compositions, and formulations for the treatment of thyroid eye disease |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
MX2010012814A (es) | 2008-05-23 | 2010-12-20 | Amira Pharmaceuticals Inc | Inhibidor de proteina activadora de 5-lipoxigenasa. |
US8163743B2 (en) | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
US20100160351A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドGlaxo Group Limited | Pi3キナーゼの阻害剤としての4−オキサジアゾール−2−イル−インダゾール |
JP2012520257A (ja) | 2009-03-10 | 2012-09-06 | グラクソ グループ リミテッド | Ikk2阻害剤としてのインドール誘導体 |
EP2408769A1 (en) | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
EP2408915A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107952A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
BRPI1009271A8 (pt) | 2009-03-19 | 2016-02-10 | Merck Sharp & Dohme | Molécula de ácido nucleico interferente curto de filamento duplo, composição farmacêutica, e, método para tratar um indivíduo humano que sofre de uma condição que é mediada pela ação, ou pela perda de ação, de bach1 |
EP2408458A1 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
JP2012521762A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた神経成長因子β鎖(NGFβ)遺伝子発現のRNA干渉媒介性阻害 |
WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
JP2012521764A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害 |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
AU2010229847A1 (en) | 2009-03-27 | 2011-10-13 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of the intercellular adhesion molecule 1 (ICAM-1)gene expression using short interfering nucleic acid (siNA) |
US8399436B2 (en) | 2009-04-24 | 2013-03-19 | Glaxo Group Limited | N-pyrazolyl carboxamides as CRAC channel inhibitors |
EP2421834A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
LT2899191T (lt) | 2009-04-30 | 2017-10-25 | Glaxo Group Limited | Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
KR20120018813A (ko) | 2009-05-29 | 2012-03-05 | 화이자 리미티드 | 글루코코티코이드 수용체 작용제 |
WO2011032175A1 (en) | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
JP2013512878A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | 新規化合物 |
US20120238571A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Indazole derivatives as pi 3-kinase |
GB2477030A (en) * | 2010-01-15 | 2011-07-20 | Lithera Inc | Lyophilised forms of fluticasone, salmeterol and combinations thereof |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
US9326987B2 (en) | 2010-09-08 | 2016-05-03 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
WO2012032067A1 (en) | 2010-09-08 | 2012-03-15 | Glaxo Group Limited | Polymorphs and salts of n- [5- [4- (5- { [(2r,6s) -2, 6 - dimethyl - 4 -morpholinyl] methyl} - 1, 3 - oxazol - 2 - yl) - 1h- inda zol-6-yl] -2- (methyloxy) - 3 - pyridinyl] methanesulfonamide |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
EP2630127A1 (en) | 2010-10-21 | 2013-08-28 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
JP5795643B2 (ja) | 2010-10-21 | 2015-10-14 | グラクソ グループ リミテッドGlaxo Group Limited | アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物 |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
CN105832681A (zh) | 2010-11-24 | 2016-08-10 | 纽赛蒂克斯公司 | 选择性、亲脂性及长效型β激动剂单一治疗调配物和用于肥胖及外形凸起的美容治疗的方法 |
US9102671B2 (en) | 2011-02-25 | 2015-08-11 | Novartis Ag | Compounds and compositions as TRK inhibitors |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
WO2014198909A1 (en) | 2013-06-14 | 2014-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Rac1 inhibitors for inducing bronchodilation |
KR20160062178A (ko) | 2013-10-17 | 2016-06-01 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 호흡기 질병의 치료를 위한 pi3k 억제제 |
JP2016537327A (ja) | 2013-10-17 | 2016-12-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 呼吸器疾患の治療のためのpi3k阻害剤 |
JP2017515840A (ja) | 2014-05-12 | 2017-06-15 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | 感染症を治療するためのダニリキシンを含む医薬組成物 |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US20190161480A1 (en) | 2016-08-08 | 2019-05-30 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US11759472B2 (en) | 2017-11-21 | 2023-09-19 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
BR112020008046A2 (pt) * | 2017-11-21 | 2020-10-27 | Axerovision, Inc. | composições e métodos de uso para tratamento de inflamação anormal em glândulas secretoras perioculares ou na superfície ocular |
JP2023519585A (ja) | 2020-03-26 | 2023-05-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | ウイルス感染を予防または治療するカテプシン阻害剤 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3943124A (en) * | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
GB1384372A (en) * | 1971-01-20 | 1975-02-19 | Glaxo Lab Ltd | Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids |
US3686978A (en) | 1971-04-09 | 1972-08-29 | Fairfied Mfg Co Inc | Plantetary reduction wheel hub |
GB1438940A (en) * | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
US4093721A (en) * | 1974-08-30 | 1978-06-06 | Glaxo Laboratories Limited | Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof |
GB1514476A (en) | 1974-08-30 | 1978-06-14 | Glaxo Lab Ltd | Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates |
GB2137206B (en) | 1980-02-15 | 1985-04-03 | Glaxo Group Ltd | Androstane 17-carbothioc acid derivatives |
SE449106B (sv) | 1980-07-10 | 1987-04-06 | Otsuka Pharma Co Ltd | Steroid med anti-inflammatorisk verkan samt komposition innehallande denna |
US4996335A (en) * | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
EP0334853B1 (en) | 1987-10-13 | 1993-06-09 | BODOR, Nicholas S. | Soft steroids having anti-inflammatory activity |
US5990099A (en) | 1988-10-31 | 1999-11-23 | Alcon Laboratories, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
AU677776B2 (en) | 1992-04-02 | 1997-05-08 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
EP0765308B1 (en) | 1994-06-15 | 2000-04-05 | The Wellcome Foundation Limited | Enzyme inhibitors |
US6172054B1 (en) | 1995-06-15 | 2001-01-09 | Alcon Laboratories, Inc. | Combination therapy for lowering and controlling intraocular pressure |
AU1970197A (en) | 1996-05-09 | 1997-11-26 | Alcon Laboratories, Inc. | Use of steroid compounds to prevent non-cancerous tissue growth |
MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
US6245804B1 (en) | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
WO1999016766A1 (fr) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Derives de benzodioxole |
CA2306026A1 (en) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Benzofuran derivatives as phosphodiesterase iv inhibitors |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
WO1999047505A1 (en) | 1998-03-14 | 1999-09-23 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone pde iii/iv inhibitors |
GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
CA2371273A1 (en) | 1999-05-04 | 2000-11-09 | Andrew Fensome | Tetracyclic progesterone receptor modulator compounds and methods |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US6263209B1 (en) | 1999-07-28 | 2001-07-17 | Motorola, Inc. | Method and apparatus in a wireless communication system for creating a learning function |
CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
GB0015876D0 (en) * | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
AR032361A1 (es) * | 2000-08-05 | 2003-11-05 | Glaxo Group Ltd | Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos |
AR035205A1 (es) | 2000-09-29 | 2004-05-05 | Glaxo Group Ltd | Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas |
JP2004522711A (ja) | 2000-11-16 | 2004-07-29 | アルコン マニュファクチャリング,リミティド | 眼内圧の低下および制御のための組み合わせ治療 |
GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
DE60224172T2 (de) | 2001-03-22 | 2008-12-04 | Glaxo Group Ltd., Greenford | Formanilid-derivative als beta2-adrenorezeptor-agonisten |
JP4446661B2 (ja) * | 2001-04-30 | 2010-04-07 | グラクソ グループ リミテッド | 抗炎症性の、17α位に環状エステル基を有するアンドロスタンの17β−カルボチオ酸エステル誘導体 |
NZ531651A (en) | 2001-09-14 | 2006-02-24 | Glaxo Group Ltd | Phenethanolamine derivatives for treatment of respiratory diseases |
GB0125259D0 (en) * | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
US6960581B2 (en) | 2002-01-14 | 2005-11-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof |
WO2003072592A1 (en) * | 2002-01-15 | 2003-09-04 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
US6831093B2 (en) | 2002-01-22 | 2004-12-14 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
WO2003082280A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
CA2477764A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
US6897224B2 (en) | 2002-04-02 | 2005-05-24 | Schering Ag | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
US7282591B2 (en) | 2002-04-11 | 2007-10-16 | Merck & Co., Inc. | 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
WO2003091204A1 (en) | 2002-04-25 | 2003-11-06 | Glaxo Group Limited | Phenethanolamine derivatives |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
AU2003281355A1 (en) | 2002-07-08 | 2004-01-23 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
AU2003251970A1 (en) | 2002-07-18 | 2004-02-09 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
US7442554B2 (en) | 2002-07-18 | 2008-10-28 | Bristol-Myers Squibb Company | Compositions and methods involving glucocorticoid receptor site II |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
DE60322713D1 (de) | 2002-08-21 | 2008-09-18 | Boehringer Ingelheim Pharma | Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung |
GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
US20060089375A1 (en) | 2002-09-16 | 2006-04-27 | Allen David G | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors |
WO2004026248A2 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
AU2003298094A1 (en) | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
US7442839B2 (en) | 2002-10-28 | 2008-10-28 | Glaxo Group Limited | Phenethanolamine derivative for the treatment of respiratory diseases |
GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
-
2003
- 2003-07-11 GB GBGB0316290.6A patent/GB0316290D0/en not_active Ceased
-
2004
- 2004-07-08 AR ARP040102427A patent/AR045900A1/es unknown
- 2004-07-08 AR ARP040102428A patent/AR045901A1/es unknown
- 2004-07-09 CN CN2004800255908A patent/CN1845933B/zh not_active Expired - Fee Related
- 2004-07-09 BR BRPI0412526-6A patent/BRPI0412526A/pt not_active Application Discontinuation
- 2004-07-09 KR KR1020067000690A patent/KR101029207B1/ko active IP Right Grant
- 2004-07-09 RU RU2005141226/04A patent/RU2359973C2/ru active
- 2004-07-09 RU RU2005141064/04A patent/RU2348645C2/ru active
- 2004-07-09 WO PCT/EP2004/007820 patent/WO2005005452A1/en active Application Filing
- 2004-07-09 PL PL04741020T patent/PL1644397T3/pl unknown
- 2004-07-09 WO PCT/EP2004/007819 patent/WO2005005451A1/en active Application Filing
- 2004-07-09 CN CN2011102290522A patent/CN102372756A/zh active Pending
- 2004-07-09 CN CN2004800256690A patent/CN1849330B/zh not_active Expired - Fee Related
- 2004-07-09 TW TW093120698A patent/TWI367888B/zh not_active IP Right Cessation
- 2004-07-09 ES ES11151276T patent/ES2433665T3/es active Active
- 2004-07-09 SI SI200432006T patent/SI1644398T1/sl unknown
- 2004-07-09 AU AU2004255855A patent/AU2004255855B2/en not_active Ceased
- 2004-07-09 NZ NZ544577A patent/NZ544577A/en unknown
- 2004-07-09 DK DK04741020.4T patent/DK1644397T3/da active
- 2004-07-09 EP EP04741020A patent/EP1644397B1/en active Active
- 2004-07-09 KR KR1020067000738A patent/KR101075324B1/ko active IP Right Grant
- 2004-07-09 US US10/564,299 patent/US7291609B2/en active Active
- 2004-07-09 MY MYPI20042752A patent/MY137944A/en unknown
- 2004-07-09 EP EP11151276.0A patent/EP2380898B1/en active Active
- 2004-07-09 DK DK04763226.0T patent/DK1644398T3/da active
- 2004-07-09 ES ES04763226T patent/ES2400821T3/es active Active
- 2004-07-09 MY MYPI20042746A patent/MY140987A/en unknown
- 2004-07-09 DE DE602004027137T patent/DE602004027137D1/de active Active
- 2004-07-09 NZ NZ544576A patent/NZ544576A/en unknown
- 2004-07-09 US US10/564,325 patent/US7288536B2/en active Active
- 2004-07-09 MX MXPA06000443A patent/MXPA06000443A/es active IP Right Grant
- 2004-07-09 AU AU2004255854A patent/AU2004255854B2/en not_active Ceased
- 2004-07-09 JP JP2006518181A patent/JP4709752B2/ja not_active Expired - Fee Related
- 2004-07-09 BR BRPI0412527-4A patent/BRPI0412527A/pt not_active Application Discontinuation
- 2004-07-09 ES ES04741020T patent/ES2343685T3/es active Active
- 2004-07-09 PL PL04763226T patent/PL1644398T3/pl unknown
- 2004-07-09 SI SI200431471T patent/SI1644397T1/sl unknown
- 2004-07-09 CA CA2531905A patent/CA2531905C/en not_active Expired - Fee Related
- 2004-07-09 CA CA2531911A patent/CA2531911C/en not_active Expired - Fee Related
- 2004-07-09 PT PT04741020T patent/PT1644397E/pt unknown
- 2004-07-09 MX MXPA06000442A patent/MXPA06000442A/es active IP Right Grant
- 2004-07-09 AT AT04741020T patent/ATE467638T1/de active
- 2004-07-09 EP EP04763226A patent/EP1644398B1/en active Active
- 2004-07-09 TW TW093120707A patent/TWI338694B/zh not_active IP Right Cessation
- 2004-07-09 JP JP2006518180A patent/JP4709751B2/ja not_active Expired - Fee Related
- 2004-07-09 PT PT47632260T patent/PT1644398E/pt unknown
-
2005
- 2005-12-22 IL IL172777A patent/IL172777A/en active IP Right Grant
- 2005-12-22 IS IS8193A patent/IS2909B/is unknown
- 2005-12-22 IS IS8194A patent/IS2776B/is unknown
- 2005-12-22 IL IL172776A patent/IL172776A/en active IP Right Grant
-
2006
- 2006-01-06 MA MA28703A patent/MA27899A1/fr unknown
- 2006-01-06 NO NO20060111A patent/NO333263B1/no not_active IP Right Cessation
- 2006-01-06 NO NO20060110A patent/NO332041B1/no not_active IP Right Cessation
- 2006-01-06 MA MA28701A patent/MA27897A1/fr unknown
- 2006-01-10 ZA ZA200600226A patent/ZA200600226B/en unknown
- 2006-01-10 ZA ZA200600223A patent/ZA200600223B/en unknown
- 2006-08-29 HK HK06109622.1A patent/HK1089186A1/xx not_active IP Right Cessation
- 2006-08-29 HK HK06109621.2A patent/HK1089185A1/xx not_active IP Right Cessation
-
2007
- 2007-09-28 US US11/863,390 patent/US7638508B2/en active Active
- 2007-09-28 US US11/863,419 patent/US20080021231A1/en not_active Abandoned
- 2007-09-28 US US11/863,439 patent/US7524970B2/en active Active
-
2009
- 2009-04-03 RU RU2009112207/04A patent/RU2009112207A/ru not_active Application Discontinuation
-
2010
- 2010-03-01 US US12/714,961 patent/US20100152148A1/en not_active Abandoned
- 2010-06-29 HR HR20100359T patent/HRP20100359T1/hr unknown
- 2010-06-30 CY CY20101100601T patent/CY1110149T1/el unknown
- 2010-12-23 IL IL210209A patent/IL210209A0/en unknown
-
2011
- 2011-01-07 JP JP2011001699A patent/JP2011093929A/ja active Pending
-
2013
- 2013-01-23 HR HRP20130056TT patent/HRP20130056T1/hr unknown
- 2013-03-19 CY CY20131100230T patent/CY1113836T1/el unknown
-
2014
- 2014-10-28 IS IS050094A patent/IS2928B/is unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101075324B1 (ko) | 항염증 활성을 가지는 특이적 글루코코르티코스테로이드화합물 | |
EP1836215B1 (en) | Androstane 17-alpha-carbonate for use in the treatment of inflammatory and allergic conditions | |
JP5281291B2 (ja) | 新規化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140929 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150930 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160929 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170919 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180918 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190917 Year of fee payment: 9 |